Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

Cancer Cell

Volumn 15, Issue 3, 2009, Pages 232-239

  Ebos, John M L ^a,b   Lee, Christina R ^a   Cruz Munoz, William ^a   Bjarnason, Georg A ^c   Christensen, James G ^d   Kerbel, Robert S ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CELLCYCLE

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB; SU 10944; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT COURSE THERAPY;

MUS;

EID: 60649087564     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.01.021     Document Type: Article

References (31)

1. Beaudry P., Nilsson M., Rioth M., Prox D., Poon D., Xu L., Zweidler-Mckay P., Ryan A., Folkman J., Ryeom S., and Heymach J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol. Cancer Ther. 7 (2008) 418-424
2. Ben Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metastasis 25 (2008) 345-356
3. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008) 592-603
4. Bidard F.C., Pierga J.Y., Vincent-Salomon A., and Poupon M.F. A "class action" against the microenvironment: do cancer cells cooperate in metastasis?. Cancer Metastasis Rev. 27 (2008) 5-10
5. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., Lehman M., Adams B.J., Bello C.L., Deprimo S.E., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26 (2008) 1810-1816
6. Casanovas O., Hicklin D., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
7. Christensen J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann. Oncol. 18 Suppl 10 (2007) x3-x10
8. de Ruiter J., Cramer S.J., Lelieveld P., and van Putten L.M. Comparison of metastatic disease after local tumour treatment with radiotherapy or surgery in various tumour models. Eur. J. Cancer Clin. Oncol. 18 (1982) 281-289
9. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. USA 104 (2007) 17069-17074
10. Ebos J.M., Lee C.R., Bogdanovic E., Alami J., Van Slyke P., Francia G., Xu P., Mutsaers A.J., Dumont D.J., and Kerbel R.S. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 68 (2008) 521-529
11. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007) 273-286
12. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., Chimenti S., Landsman L., Abramovitch R., and Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
13. Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., Kloeters C., Rief M., Rogalla P., Miller K., and Grunwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur. Urol. (2008) 10.1016/j.eururo.2008.10.021 Published online October 18, 2008
14. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
15. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
16. Man S., Munoz R., and Kerbel R.S. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev. 26 (2007) 737-747
17. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116 (2006) 2610-2621
18. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., Reinhardt F., Harris L.N., Hylander B.L., Repasky E.A., and Weinberg R.A. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133 (2008) 994-1005
19. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 15 (2006) 553-561
20. Munoz R., Man S., Shaked Y., Lee C., Wong J., Francia G., and Kerbel R.S. Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66 (2006) 3386-3391
21. Natori T., Sata M., Washida M., Hirata Y., Nagai R., and Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem. Biophys. Res. Commun. 297 (2002) 1058-1061
22. Noonan D.M., De Lerma B.A., Vannini N., Mortara L., and Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 27 (2008) 31-40
23. Okazaki T., Ebihara S., Asada M., Kanda A., Sasaki H., and Yamaya M. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int. Immunol. 18 (2006) 1-9
24. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., and Casanovas O. Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231 this issue
25. Shojaei F., Singh M., Thompson J.D., and Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl. Acad. Sci. USA 105 (2008) 2640-2645
26. Shuch B., Riggs S.B., Larochelle J.C., Kabbinavar F.F., Avakian R., Pantuck A.J., Patard J.J., and Belldegrun A.S. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102 (2008) 692-696
27. van Putten L.M., Kram L.K., van Dierendonck H.H., Smink T., and Fuzy M. Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. Int. J. Cancer 15 (1975) 588-595
28. Vollmer T.L., and Conley F.K. Effect of cyclophosphamide on survival of mice and incidence of metastatic tumor following intravenous and intracardial inoculation of tumor cells. Cancer Res. 44 (1984) 3902-3906
29. von Mehren M. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. Curr. Opin. Oncol. 20 (2008) 428-432
30. Wai P.Y., and Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 27 (2008) 103-118
31. Zhang W., Stoica G., Tasca S.I., Kelly K.A., and Meininger C.J. Modulation of tumor angiogenesis by stem cell factor. Cancer Res. 60 (2000) 6757-6762